[⁸⁹Zr]Zr-girentuximab PET-CT has a favorable safety profile and is a highly accurate noninvasive imaging modality for the detection and characterization of clear-cell renal cell carcinoma (RCC), according to ZIRCON trial data. ZIRCON was a prospective, open-label, multicenter, phase 3 trial that included patients aged 18 years or older with an indeterminate renal mass ≤7 cm suspicious for clear-cell RCC and scheduled for nephrectomy. ...
Renal Cell Carcinoma Diagnostics
Advertisement
In anticipation of ESMO, Dr. Katy Beckermann previews various clinical trials and studies to be presented in kidney cancer.
ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth
The group discusses how blocking ACSS2 may affect immune cells in the tumor microenvironment. 
Drs. Beckermann, Rathmell, and Bacigalupa highlight the potential of ACSS2 as a therapeutic target in kidney cancer.
Researchers evaluated the tissue samples of 126 treatment-naïve patients collected from a multicenter database.
Dr. Simpa Salami's research into a 15-gene prognostic signature for predicting ccRCC risk is discussed in this interview.
ACSS2 inhibition led to lowered chromatin accessibility, HIF-2α expression, and stability.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
The signature has been initially validated to improve ccRCC risk stratification and provide better treatment allocation.
The use of 89Zr PET/CT and subsequent surgery in patients treated with it demonstrated low radiation exposure levels.
Drs. Xu and Joyce explain the rationale behind recent research on plasma KIM-1, its significance as a biomarker, and more.
Advertisement
Video Insights
Conferene Coverage
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Advertisement
Section Editor
Daniel Joyce, MDDepartment of Urology | Vanderbilt University Medical Center
Get the latest RCC research straight to your inbox.
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.